The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Alzheimer's Disease Diagnostic-Global Market Insights and Sales Trends 2025
Synopsis
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The global Alzheimer's Disease Diagnostic market size is expected to reach US$ 4024.3 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Alzheimer's Disease Diagnostic in various end use industries. The expanding demands from the Clinics, Hospitals, Diagnostic Centers and Other, are propelling Alzheimer's Disease Diagnostic market. Genetic Testing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Neurological Exam segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alzheimer's Disease Diagnostic, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alzheimer's Disease Diagnostic market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alzheimer's Disease Diagnostic market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alzheimer's Disease Diagnostic sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alzheimer's Disease Diagnostic covered in this report include Eli Lilly, TauRx, Alector, Accera, Treventis, Neuro-Bio and Cognition Therapeutics, etc.
The global Alzheimer's Disease Diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
TauRx
Alector
Accera
Treventis
Neuro-Bio
Cognition Therapeutics
Global Alzheimer's Disease Diagnostic market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alzheimer's Disease Diagnostic market, Segment by Type:
Genetic Testing
Neurological Exam
Mini-Mental State Exam(MMSE)
Brain Imaging
Other
Global Alzheimer's Disease Diagnostic market, by Application
Clinics
Hospitals
Diagnostic Centers
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Alzheimer's Disease Diagnostic companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The global Alzheimer's Disease Diagnostic market size is expected to reach US$ 4024.3 million by 2029, growing at a CAGR of 1.5% from 2023 to 2029. The market is mainly driven by the significant applications of Alzheimer's Disease Diagnostic in various end use industries. The expanding demands from the Clinics, Hospitals, Diagnostic Centers and Other, are propelling Alzheimer's Disease Diagnostic market. Genetic Testing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Neurological Exam segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Alzheimer's Disease Diagnostic, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Alzheimer's Disease Diagnostic market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Alzheimer's Disease Diagnostic market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Alzheimer's Disease Diagnostic sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Alzheimer's Disease Diagnostic covered in this report include Eli Lilly, TauRx, Alector, Accera, Treventis, Neuro-Bio and Cognition Therapeutics, etc.
The global Alzheimer's Disease Diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
TauRx
Alector
Accera
Treventis
Neuro-Bio
Cognition Therapeutics
Global Alzheimer's Disease Diagnostic market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Alzheimer's Disease Diagnostic market, Segment by Type:
Genetic Testing
Neurological Exam
Mini-Mental State Exam(MMSE)
Brain Imaging
Other
Global Alzheimer's Disease Diagnostic market, by Application
Clinics
Hospitals
Diagnostic Centers
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Alzheimer's Disease Diagnostic companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Alzheimer's Disease Diagnostic
1.1 Alzheimer's Disease Diagnostic Market Overview
1.1.1 Alzheimer's Disease Diagnostic Product Scope
1.1.2 Alzheimer's Disease Diagnostic Market Status and Outlook
1.2 Global Alzheimer's Disease Diagnostic Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Alzheimer's Disease Diagnostic Market Size by Region (2018-2029)
1.4 Global Alzheimer's Disease Diagnostic Historic Market Size by Region (2018-2023)
1.5 Global Alzheimer's Disease Diagnostic Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Alzheimer's Disease Diagnostic Market Size (2018-2029)
1.6.1 North America Alzheimer's Disease Diagnostic Market Size (2018-2029)
1.6.2 Europe Alzheimer's Disease Diagnostic Market Size (2018-2029)
1.6.3 Asia-Pacific Alzheimer's Disease Diagnostic Market Size (2018-2029)
1.6.4 Latin America Alzheimer's Disease Diagnostic Market Size (2018-2029)
1.6.5 Middle East & Africa Alzheimer's Disease Diagnostic Market Size (2018-2029)
2 Alzheimer's Disease Diagnostic Market by Type
2.1 Introduction
2.1.1 Genetic Testing
2.1.2 Neurological Exam
2.1.3 Mini-Mental State Exam(MMSE)
2.1.4 Brain Imaging
2.1.5 Other
2.2 Global Alzheimer's Disease Diagnostic Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Alzheimer's Disease Diagnostic Historic Market Size by Type (2018-2023)
2.2.2 Global Alzheimer's Disease Diagnostic Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Alzheimer's Disease Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Alzheimer's Disease Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Alzheimer's Disease Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Alzheimer's Disease Diagnostic Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Alzheimer's Disease Diagnostic Revenue Breakdown by Type (2018-2029)
3 Alzheimer's Disease Diagnostic Market Overview by Application
3.1 Introduction
3.1.1 Clinics
3.1.2 Hospitals
3.1.3 Diagnostic Centers
3.1.4 Other
3.2 Global Alzheimer's Disease Diagnostic Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Alzheimer's Disease Diagnostic Historic Market Size by Application (2018-2023)
3.2.2 Global Alzheimer's Disease Diagnostic Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Alzheimer's Disease Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Alzheimer's Disease Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Alzheimer's Disease Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Alzheimer's Disease Diagnostic Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Alzheimer's Disease Diagnostic Revenue Breakdown by Application (2018-2029)
4 Alzheimer's Disease Diagnostic Competition Analysis by Players
4.1 Global Alzheimer's Disease Diagnostic Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alzheimer's Disease Diagnostic as of 2022)
4.3 Date of Key Players Enter into Alzheimer's Disease Diagnostic Market
4.4 Global Top Players Alzheimer's Disease Diagnostic Headquarters and Area Served
4.5 Key Players Alzheimer's Disease Diagnostic Product Solution and Service
4.6 Competitive Status
4.6.1 Alzheimer's Disease Diagnostic Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Eli Lilly
5.1.1 Eli Lilly Profile
5.1.2 Eli Lilly Main Business
5.1.3 Eli Lilly Alzheimer's Disease Diagnostic Products, Services and Solutions
5.1.4 Eli Lilly Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.1.5 Eli Lilly Recent Developments
5.2 TauRx
5.2.1 TauRx Profile
5.2.2 TauRx Main Business
5.2.3 TauRx Alzheimer's Disease Diagnostic Products, Services and Solutions
5.2.4 TauRx Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.2.5 TauRx Recent Developments
5.3 Alector
5.3.1 Alector Profile
5.3.2 Alector Main Business
5.3.3 Alector Alzheimer's Disease Diagnostic Products, Services and Solutions
5.3.4 Alector Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.3.5 Accera Recent Developments
5.4 Accera
5.4.1 Accera Profile
5.4.2 Accera Main Business
5.4.3 Accera Alzheimer's Disease Diagnostic Products, Services and Solutions
5.4.4 Accera Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.4.5 Accera Recent Developments
5.5 Treventis
5.5.1 Treventis Profile
5.5.2 Treventis Main Business
5.5.3 Treventis Alzheimer's Disease Diagnostic Products, Services and Solutions
5.5.4 Treventis Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.5.5 Treventis Recent Developments
5.6 Neuro-Bio
5.6.1 Neuro-Bio Profile
5.6.2 Neuro-Bio Main Business
5.6.3 Neuro-Bio Alzheimer's Disease Diagnostic Products, Services and Solutions
5.6.4 Neuro-Bio Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.6.5 Neuro-Bio Recent Developments
5.7 Cognition Therapeutics
5.7.1 Cognition Therapeutics Profile
5.7.2 Cognition Therapeutics Main Business
5.7.3 Cognition Therapeutics Alzheimer's Disease Diagnostic Products, Services and Solutions
5.7.4 Cognition Therapeutics Alzheimer's Disease Diagnostic Revenue (US$ Million) & (2018-2023)
5.7.5 Cognition Therapeutics Recent Developments
6 North America
6.1 North America Alzheimer's Disease Diagnostic Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Alzheimer's Disease Diagnostic Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alzheimer's Disease Diagnostic Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alzheimer's Disease Diagnostic Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alzheimer's Disease Diagnostic Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alzheimer's Disease Diagnostic Market Dynamics
11.1 Alzheimer's Disease Diagnostic Industry Trends
11.2 Alzheimer's Disease Diagnostic Market Drivers
11.3 Alzheimer's Disease Diagnostic Market Challenges
11.4 Alzheimer's Disease Diagnostic Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
